3,4-dihydroxyphenylacetic acid has been researched along with aconitine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardo, MT; Beckmann, JS; Crooks, PA; Denehy, ED; Dwoskin, LP; Horton, DB; Nickell, JR; Siripurapu, KB; Vartak, A | 1 |
1 other study(ies) available for 3,4-dihydroxyphenylacetic acid and aconitine
| Article | Year |
|---|---|
The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aconitine; Amphetamine-Related Disorders; Animals; Behavior, Animal; Cell Membrane; Conditioning, Operant; Corpus Striatum; Dopamine; Drug Tolerance; Lobeline; Male; Methamphetamine; Nicotine; Protein Binding; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptors, Nicotinic; Reinforcement, Psychology; Self Administration; Synaptic Vesicles; Tetrabenazine; Vesicular Monoamine Transport Proteins | 2010 |